# An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

> **NCT03352323** · PHASE3 · COMPLETED · sponsor: **Padagis LLC** · enrollment: 50 (actual)

## Conditions studied

- Rosacea
- Erythema

## Interventions

- **DRUG:** Oxymetazoline

## Key facts

- **NCT ID:** NCT03352323
- **Lead sponsor:** Padagis LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-18
- **Primary completion:** 2017-12-06
- **Final completion:** 2018-03-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352323, "An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03352323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*